Keytruda (pembrolizumab) Disease area(s): Oncology Manufacturer(s): Merck 2024 Sales (USD): $29.48 billion Why it sold so well: Mercks flagship cancer immunotherapy Keytruda achieved expected, remarkable success in 2024, with global sales reaching $29.48 billion an 18% increase from the previous year and accounting for 46% of the companys total revenue
With targeted peptide protocols, we can help support your bodys ability to burn fat, build lean muscle, improve recovery, regulate hormones, and more
But you may be less familiar with semaglutide , the active ingredient behind these two brand-name drugs (as well as another medication, called Rybelsus)
2026 BCBS Mental Health Coverage Updates Several important developments in 2026 have expanded mental health coverage for Blue Cross Blue Shield members across many states
2 3 What do I do if I have side effects
Polimeros 20, 287297